As the co-founder and CEO of Modulari-T Bio, a Y Combinator-backed biotech startup, I am passionate about creating novel cell therapies for cancer and other diseases. My vision is to leverage structural and synthetic biology to reprogram immune cells to better recognize and attack cancer cells using our MARC platform, which has the potential to revolutionize the field of immunotherapy.

My background in molecular biology, biochemistry, and cell biology, as well as my experience in developing and optimizing assays for high-throughput screening of small molecules, has equipped me with the skills and knowledge to lead a multidisciplinary team of scientists and engineers. I have published multiple papers in peer-reviewed journals, filed a patent for a system and method to monitor protein complex formation in cells, and received several awards and honors for my research. I am also an alumni of the life sciences entrepreneurship development program at Concordia University and Y Combinator, where I learned how to translate scientific discoveries into viable products and businesses.

• 

  Co-founder & CEO in Modulari-T

  Sophisticated Receptors For Next-Generation Cell Therapies.